DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Human Drugs For Veterinary Use - Current Trends and Future Commercial Prospects for Crossover Drugs" report to their offering.
This report provides an in-depth analysis of Extra-label Drug Use (ELDU), its application in the veterinary setting and other guidelines and regulations followed by professionals in the animal health industry.
Through a series of in-depth case studies this report provides insights into the rationale for the transition of several human drugs to the veterinary setting as well as disease overviews, competing treatments, manufacturer information, dosage forms, cost of therapy and other insightful marketing information. Our new study also identifies and explores important drivers and restraints of the crossover drugs market.
- What regulations need to be followed when prescribing human drugs off-label to pets and food-producing animals?
- What are the main factors driving the prescription of human medicines in animals?
- Marketed human drugs commonly used in companion animals
- What are the differences in indication between the human and veterinary setting?
- What are the dosage and side effects of those specific drugs in animals?
Key Reasons to Purchase
- Gain insightful analyses and understanding of the crossover drugs market: This report describes and assesses the key differences between the human and animal healthcare markets, areas of unmet need in the veterinary market and key factors responsible for ELDU in the veterinary setting.
- Assess high-profile marketed human products used for treating animals: Our new study provides analyses of the key human therapies that have the potential to be transitioned in the veterinary space.
- Identify the most important drivers and restraints of the crossover drugs market: This report provides insights regarding what is currently driving the prescription and application of human drugs in the veterinary setting as well as the current factors restraining further transition.
- Boehringer Ingelheim Vetmedica
- Elanco (Eli Lilly)
- Merck/MSD Animal Health
- Merial (Sanofi)
For more information about this report visit http://www.researchandmarkets.com/research/rf65v9/human_drugs_for
Related Topics: Animal Healthcare/Veterinary